We are entering a new era for treatment and diagnosis of CNS disorders with unique developments from biopharma, academia and tech that challenge the status quo. Innovators are applying Silicon Valley's quick, decisive approach to CNS drug development, leveraging human and real world data vs. simply looking at p-values, and bringing to bear digital and AI technologies. The panel will explore these new developments and what’s needed to solve mental health’s biggest challenges.

Session ID: 410185